Tovetumab

Tovetumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Merck & Co.

History

Tovetumab was one of many experimental drugs developed in the early 21st century to combat various forms of cancer. It was developed by Merck & Co, a multinational pharmaceutical company based in the United States.

Mechanism of Action

As a monoclonal antibody, Tovetumab works by targeting and attaching to specific proteins on the surface of cancer cells. This allows the immune system to better recognize and attack these cells.

Clinical Trials

Tovetumab has undergone various clinical trials to test its safety and efficacy. These trials are crucial steps in the drug development process, and they help determine whether a drug should be approved for use.

Side Effects

Like all drugs, Tovetumab can cause side effects. These can vary widely from patient to patient, and they can include both physical and psychological symptoms.

See Also

• Monoclonal antibodies
• Cancer treatment
• Clinical trials
• Merck & Co

References

<references />

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia